Axogen, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
AXGN$50.64+1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Exhibit Index
(b)Exhibits
The following exhibits are included in this Annual Report on Form 10-K or incorporated by reference in the Form 10-K.
| Exhibit Number | Description | Filings Referenced for Incorporation by Reference |
| 3.1 | Amended and Restated Articles of Incorporation of Axogen, Inc. | November 6, 2019, Form 10-Q, Exhibit 3.1 |
| 3.2 | Axogen, Inc. Amended and Restated Bylaws dated as of August 15, 2023 | March 5, 2024, Form 10-K, Exhibit 3.2 |
| †10.2.1 | Amended and Restated Standard Exclusive License Agreement with Sublicensing Terms, dated as of February 21, 2006, by and between Axogen Corporation and the University of Florida Research Foundation, Inc. | October 6, 2011, Form 8-K, Exhibit 10.2 |
| 10.2.2 | Second Amendment to the Amended and Restated Standard Exclusive License Agreement No. A5140, effective as of July 5, 2016, by and between Axogen Corporation and the University of Florida Research Foundation, Inc. | July 11, 2016, Form 8-K, Exhibit 10.2.1 |
| 10.2.3 | Third Amendment to the Amended and Restated Standard Exclusive License Agreement No. A5140 effective as of October 19, 2021, by and between AxoGen, Inc. and the University of Florida Research Foundation, Inc. | March 14, 2023, Form 10-K Exhibit 10.2.3 |
| Exhibit Number | Description | Filings Referenced for Incorporation by Reference |
| *10.3 | Sid Martin Biotechnology Development Institute Incubator License Agreement, dated as of September 26, 2006, by and between Axogen, Inc. and the University of Florida Research Foundation, Inc. | October 6, 2011, Form 8-K, Exhibit 10.3 |
| †10.4.1 | Amended and Restated Nerve Tissue Processing Agreement, dated as of February 27, 2008, by and between Axogen Corporation and LifeNet Health | October 6, 2011, Form 8-K, Exhibit 10.4.1 |
| †10.4.2 | Second Amendment to Amended and Restated Nerve Tissue Processing Agreement, dated as of August 9, 2011, by and between Axogen Corporation and LifeNet Health | October 6, 2011, Form 8-K , Exhibit 10.4.2 |
| †10.5.1 | Distribution Agreement, dated as of August 27, 2008, by and between Axogen, Inc. and Cook Biotech Incorporated | October 6, 2011, Form 8-K , Exhibit 10.5 |
| 10.5.2 | Amendment No. 1 to Distribution Agreement, dated as of February 24, 2012, by and between Axogen, Inc. and Cook Biotech Incorporated | March 15, 2012, Form 10-K, Exhibit 10.5.2 |
| 10.5.3 | Amendment No. 2 to Distribution Agreement, dated as of February 26, 2018, by and between Axogen, Inc. and Cook Biotech Incorporated | March 1, 2017, Form 10-K, Exhibit 10.5.3 |
| 10.5.4 | Amendment No. 3 to Distribution Agreement, dated as of August 4, 2023, by and between Axogen, Inc. and Cook Biotech Incorporated | August 8, 2023, Form 10-Q, Exhibit 10.3.3 |
| 10.6.1 | Lease dated as of February 6, 2007, by and between Axogen Corporation and WIGSHAW, LLC | November 14, 2011, Form 10-Q, Exhibit 10.10 |
| 10.6.2 | Amendment dated February 27, 2012 to lease dated as of February 6, 2007, by and between Axogen Corporation and WIGSHAW, LLC, its successors and assigns | March 15, 2012, Form 10-K, Exhibit 10.23 |
| 10.6.3 | Second Amendment to Lease, dated as of February 27, 2013 to lease dated as of February 6, 2007, by and between Axogen Corporation and SNH Medical Office Properties Trust | March 12, 2013, Form 10-K, Exhibit 10.23 |
| 10.6.4 | Third Amendment to Lease, dated November 12, 2013 to lease dated as of February 6, 2007, by and between Axogen Corporation and SNH Medical Office Properties Trust | March 6, 2014, Form 10-K, Exhibit 10.10.3 |
| 10.6.5 | Fourth Amendment to Lease, dated as of March 16, 2016, by and between Axogen Corporation and SNH Medical Office Properties Trust | March 18, 2016, Form 8-K, Exhibit 10.10.4 |
| 10.6.6 | Fifth Amendment to Lease, dated as of November 30, 2020, by and between AxoGen Corporation and SNH Medical Office Properties Trust | December 4, 2020, Form 8-K, Exhibit 10.9.5 |
| 10.6.7 | Sixth Amendment to Lease, dated as of July 13, 2021, by and between Axogen Corporation and Ology Bioservices Holdings, LLC | July 16, 2021, Form 8-K, Exhibit 10.2 |
| 10.6.8 | Current Premises Election Notice, dated as of April 10, 2018, by and between Axogen Corporation and SNH Medical Office Properties Trust | April 13, 2018, Form 8-K, Exhibit 10.1 |
| 10.6.9 | Letter Agreement effective September 20, 2018 by between Axogen Corporation and SNH Medical Office Properties Trust | September 21, 2018, Form 8-K, Exhibit 10.1 |
| *10.7 | Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 | April 8, 2016, Definitive Proxy Statement, Appendix A |
| *10.8.1 | Form of Employee Incentive Stock Option Agreement | September 26, 2007, Form 8-K, Exhibit 99.2 |
| *10.8.2 | Amended Form of Employee Incentive Stock Option Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 | March 1, 2017, Form 10-K, Exhibit 10.10.2 |
| 10.9.1 | Commercial Lease, dated April 21, 2015, by and between Axogen Corporation and Ja-Cole, L.P. | April 22, 2015, Form 8-K, Exhibit 10.1 |
| 10.9.2 | Addendum to Commercial Lease, dated April 21, 2015 by and between Axogen Corporation and Ja-Cole, L.P. | April 22, 2015, Form 8-K, Exhibit 10.2 |
| Exhibit Number | Description | Filings Referenced for Incorporation by Reference |
| 10.9.3 | Commercial Lease Amendment 2, dated as of October 25, 2016, by and between Axogen Corporation and Ja-Cole L.P. | October 31, 2016, Form 8-K, Exhibit 10.2.1 |
| 10.9.4 | Commercial Lease Amendment 3, dated November 21, 2018 by and between Ja-Cole L.P. and Axogen Corporation | November 26, 2018, Form 8-K, Exhibit 10.1 |
| 10.9.5 | Commercial Lease Amendment 4, dated March 12, 2019, by and between Ja-Cole L.P. and Axogen Corporation | May 8, 2019, Form 10-Q, Exhibit 10.1 |
| 10.9.6 | Commercial Lease Amendment, dated as of January 27, 2022, by and between Ja-Cole L.P. and Axogen Corporation | January 31, 2022, Form 8-K, Exhibit 10.1 |
| 10.9.7 | Commercial Lease Amendment 6, dated March 10, 2023, by and between Ja-Cole L.P. and Axogen, Inc | March 5, 2024, Form 10-K, Exhibit 10.9.7 |
| 10.9.8 | Commercial Lease Amendment, dated May 9, 2023, by and between Ja-Cole L.P. and Axogen, Inc | March 5, 2024, Form 10-K, Exhibit 10.9.8 |
| 10.10.1 | License and Services Agreement, dated as of August 6, 2015, by and between Axogen Corporation and Community Blood Center (d/b/a Community Tissue Services) | November 5, 2015, Form 10-Q, Exhibit 10.3 |
| 10.10.2 | Fourth Amendment to License and Services Agreement, dated as of February 22, 2019, by and between Axogen Corporation and Community Blood Center (d/b/a Community Tissue Services) | February 26, 2019, Form 10-K, Exhibit 10.13.1 |
| 10.10.3 | Seventh Amendment to License and Services Agreement, dated as of February 22, 2021, by and between Axogen Corporation and Community Blood Center (d/b/a Community Tissue Services) | February 26, 2021, Form 8-K, Exhibit 10.1 |
| 10.10.4 | Eighth Amendment to License and Services Agreement, dated as of August 22, 2022, by and between Axogen Corporation and Community Blood Center (d/b/a Community Tissue Services) | August 25, 2022, Form 8-K, Exhibit 10.2 |
| 10.10.5 | Ninth Amendment to License and Services Agreement, dated as of December 21, 2023, by and between Axogen Corporation and Community Blood Center (d/b/a Community Tissue Services) | March 5, 2024, Form 10-K, Exhibit 10.10.5 |
| 10.11 | Form of Non-Incentive Stock Option Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 | March 1, 2017, Form 10-K, Exhibit 10.22 |
| *†10.12 | Form of Performance Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of May 26, 2016 | March 1, 2017, Form 10-K, Exhibit 10.23 |
| *10.13 | Form of 2018 Performance Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 | March 1, 2018, Form 10-K, Exhibit 10.26 |
| *10.14 | Form of Restricted Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 | March 1, 2017, Form 10-K, Exhibit 10.28 |
| 10.15 | Current Premises Election Notice, dated as of April 10, 2018, by and between Axogen Corporation and SNH Medical Office Properties Trust | April 13, 2018, Form 8-K, Exhibit 10.1 |
| 10.16 | Letter Agreement effective September 20, 2018 by between Axogen Corporation and SNH Medical Office Properties Trust | September 21, 2018, Form 8-K, Exhibit 10.1 |
| 10.17.1 | Office Lease dated September 20, 2018 by and between Axogen, Inc., Axogen Corporation and Heights Union, LLC | September 21, 2018, Form 8-K, Exhibit 10.2 |
| 10.17.2 | First Amendment to Office Lease, dated as of July 12, 2021, by and among Axogen, Inc., Axogen Corporation, and Heights Union I, LLC | July 16, 2021, Form 8-K, Exhibit 10.1 |
| *10.18 | Form of Incentive Stock Option Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of October 29, 2018 | October 29, 2018, Form 8-K, Exhibit 10.3 |
| Exhibit Number | Description | Filings Referenced for Incorporation by Reference |
| *10.19 | Form of Restricted Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of October 29, 2018 | October 29, 2018, Form 8-K, Exhibit 10.4 |
| 10.2 | Axogen, Inc. 2017 Employee Stock Purchase Plan | April 7, 2017, Definitive Proxy Statement, Appendix B |
| 10.21.1 | Lease, dated November 19, 2018 by and between SNH Medical Office Properties Trust and Axogen Corporation | November 26, 2018, Form 8-K, Exhibit 10.3 |
| 10.21.2 | First Amendment to Lease dated as of November 19, 2018 by and between SNH Medical Office Properties Trust and Axogen Corporation | November 26, 2018, Form 8-K, Exhibit 10.4 |
| 10.21.3 | Second Amendment to Lease dated as of January 1, 2023 by and between SNH Medical Office Properties Trust and Axogen Corporation | March 14, 2023, Form 10-K, Exhibit 10.25.3 |
| *10.22 | Form of Performance Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of April 5, 2017 | February 26, 2019, Form 10-K, Exhibit 10.47 |
| 10.23 | Standard Form of Agreement Between Owner and Design-Builder, dated as of July 9, 2019, by and between Axogen Corporation and CRB Builders, LLC | July 9, 2019, Form 8-K, Exhibit 10.1 |
| *10.24 | Axogen Inc. 2019 Long-Term Incentive Plan and forms of award notices and agreements thereunder | November 6, 2019, Form 10-Q, Exhibit 10.2 |
| ††10.25.1 | Nerve End Cap Supply Agreement, dated June 27, 2017, by and between Cook Biotech Incorporated and Axogen Corporation | February 24, 2020, Form 10-K, Exhibit 10.51 |
| 10.25.2 | First Amendment to Nerve End Cap Supply Agreement, dated April 6, 2020, by and between Cook Biotech Incorporated and AxoGen Corporation | March 14, 2023, Form 10-K, Exhibit 10.25.3 |
| 10.25.3 | Second Amendment to Nerve End Cap Supply dated August 4, 2023, by and between Cook Biotech Incorporated and Axogen Corporation | August 8, 2023, Form 10-Q, Exhibit 10.2.2 |
| 10.26.1 | Term Loan Agreement, dated June 30, 2020, among Axogen, Inc., Axogen Corporation, AxoGen Processing Corporation, TPC Investments II LP and Argo SA LLC | July 1, 2020, Form 8-K, Exhibit 10.1 |
| 10.26.2 | Amendment No. 1 to the Term Loan Agreement, dated June 29, 2023, by and between Axogen, Inc., Axogen Corporation, AxoGen Processing Corporation, TPC Investments II LP, and Argo SA LLC | June 30, 2023, Form 8-K, Exhibit 10.1 |
| 10.27 | Security Agreement, dated June 30, 2020, among Axogen, Inc., Axogen Corporation, AxoGen Processing Corporation, and Argo SA LLC | July 1, 2020, Form 8-K, Exhibit 10.2 |
| 10.28 | Revenue Participation Agreement, dated June 30, 2020, between Axogen, Inc. and Argo SA LLC | July 1, 2020, Form 8-K, Exhibit 10.3 |
| 10.29 | Option Agreement, dated June 30, 2020, between Axogen, Inc. and TPC Investments II LP | July 1, 2020, Form 8-K, Exhibit 10.4 |
| *10.30 | Amended and Restated Employment Agreement, dated November 1, 2020, by and between Axogen Corporation and Karen Zaderej | October 29, 2020, Form 8-K, Exhibit 10.1 |
| *10.31 | Employment Agreement, dated December 4, 2023, by and between Axogen Corporation and Nir Naor | December 6, 2023, Form 8-K, Exhibit 10.1 |
| 10.32.1 | Commercial Lease, dated October 1, 2020, by and between Axogen Corporation and Ja-Cole, L.P. | October 30, 2020, Form 10-Q, Exhibit 10.1 |
| 10.32.2 | First Amendment to Lease Agreement dated as of August 22, 2022, by and between Axogen Corporation and Ja-Cole, L.P. | August 25, 2022, Form 8-K, Exhibit 10.1 |
| *10.33 | Axogen, Inc. Amended and Restated 2019 Long-Term Incentive Plan | March 31, 2021, Definitive Proxy Statement, Appendix A |
| *10.34 | Form of Performance-Based Restricted Stock Units Notice and Performance-Based Restricted Stock Units Agreement under the Axogen, Inc. Amended and Restated 2019 Long-Term Incentive Plan | April 1, 2022, Form 8-K, Exhibit 10.1 |
| Exhibit Number | Description | Filings Referenced for Incorporation by Reference |
| *10.35 | Form of Restricted Stock Units Notice and Restricted Stock Units Agreement under the Axogen, Inc. Amended and Restated 2019 Long-Term Incentive Plan | April 1, 2022, Form 8-K, Exhibit 10.2 |
| *10.36 | Form of Incentive Stock Options Notice and Incentive Stock Option Agreement under the Axogen, Inc. Amended and Restated 2019 Long-Term Incentive Plan | April 1, 2022, Form 8-K, Exhibit 10.3 |
| *10.37 | Form of Premium Incentive Stock Options Notice and Premium Incentive Stock Option Agreement under the Axogen, Inc. Amended and Restated 2019 Long-Term Incentive Plan | April 1, 2022, Form 8-K, Exhibit 10.4 |
| *10.38 | Axogen, Inc. Second Amended and Restated 2019 Long-Term Incentive Plan | April 14, 2022, Definitive Proxy Statement, Appendix A |
| 10.39 | Axoguard HA+ Nerve Protector Supply and Manufacturing Agreement, dated May 2, 2023, by and between Cook Biotech Incorporated and Axogen Corporation | March 5, 2024, Form 10-K, Exhibit 10.51 |
| *10.41 | Form of Restricted Stock Unit Agreement under the Axogen, Inc. Inducement Equity Incentive Plan | March 5, 2024, Form 10-K, Exhibit 10.53 |
| *†††10.42 | Form of Performance-Based Restricted Stock Units Notice Under the Axogen Inc. Amended and Restated 2019 Long-Term Incentive Plan (TSR) | March 5, 2024, Form 10-K, Exhibit 10.54 |
| *†††10.43 | Form of Performance-Based Restricted Stock Units Notice Under the Axogen Inc. Amended and Restated 2019 Long-Term Incentive Plan (Performance Goal) | March 5, 2024, Form 10-K, Exhibit 10.55 |
| *10.44.1 | Employment Agreement, dated February 27, 2023, by and between Axogen Corporation and Marc Began | March 5, 2024, Form 10-K, Exhibit 10.56 |
| *10.44.2 | Amendment No. 1 to Executive Employment Agreement, dated February 27, 2024, by and between Axogen Corporation and Marc Began | March 5, 2024, Form 10-K, Exhibit 10.57 |
| *10.45 | Amended and Restated Confidentiality, Intellectual Property, Non-Competition and Non-Solicitation Agreement, dated February 27, 2024, by and between Axogen Corporation and Marc Began | March 5, 2024, Form 10-K, Exhibit 10.58 |
| *10.46.1 | Employment Agreement, dated February 13, 2023, by and between Axogen Corporation and Jens Kemp | March 5, 2024, Form 10-K, Exhibit 10.59 |
| *10.46.2 | Amendment No. 1 to Executive Employment Agreement, dated February 27, 2024, by and between Axogen Corporation and Jens Kemp | March 5, 2024, Form 10-K, Exhibit 10.60 |
| *10.47 | Amended and Restated Confidentiality, Intellectual Property, Non-Competition and Non-Solicitation Agreement, dated February 27, 2024, by and between Axogen Corporation and Jens Kemp | March 5, 2024, Form 10-K, Exhibit 10.61 |
| *10.48.1 | Employment Agreement, dated February 27, 2024, by and between Axogen Corporation and Erick DeVinney | March 5, 2024, Form 10-K, Exhibit 10.62 |
| *10.48.2 | Amendment No. 1 to Executive Employment Agreement, dated February 27, 2024, by and between Axogen Corporation and Erick DeVinney | March 5, 2024, Form 10-K, Exhibit 10.63 |
| *10.49 | Amended and Restated Confidentiality, Intellectual Property, Non-Competition and Non-Solicitation Agreement, dated February 27, 2024, by and between Axogen Corporation and Erick DeVinney | March 5, 2024, Form 10-K, Exhibit 10.64 |
| *10.50 | Transition and Separation Agreement, dated January 4, 2024, between the Company and Karen Zaderej | January 4, 2024, Form 8-K, Exhibit 10.1 |
| *10.51 | Executive Employment Agreement, dated August 9, 2024, between the Company and Michael Dale | August 9, 2024, Form 8-K, Exhibit 10.1 |
| Exhibit Number | Description | Filings Referenced for Incorporation by Reference |
| *10.52 | Axogen, Inc. Performance-Based Restricted Stock Units Notice Inducement Award Agreement, effective as of August 9, 2024, by and between the Company and Michael Dale (TSR) | August 9, 2024, Form 8-K, Exhibit 10.2 |
| *10.53 | Axogen, Inc. Performance-Based Restricted Stock Units Notice Inducement Award Agreement, effective as of August 9, 2024, by and between the Company and Michael Dale (Performance) | August 9, 2024, Form 8-K, Exhibit 10.3 |
| *10.54 | Axogen, Inc. Third Amended and Restated 2019 Long-Term Incentive Plan | April 24, 2024, Definitive Proxy Statement, Appendix A |
| *10.55 | Axogen, Inc. Fourth Amended and Restated 2019 Long-Term Incentive Plan | April 30, 2025, Definitive Proxy Statement, Appendix A |
| *10.56 | Separation Agreement, dated May 7, 2025, by and between Axogen Corporation and Nir Naor | May 8, 2025, Form 8-K, Exhibit 10.1 |
| *10.57 | Employment Agreement, dated May 7, 2025, by and between Axogen Corporation and Lindsey Hartley | May 8, 2025, Form 8-K, Exhibit 10.2 |
| *10.58 | Amended and Restated Confidentiality, Intellectual Property, Non-Competition and Non-Solicitation Agreement, dated December 5, 2025, by and between Axogen Corporation and Lindsey Hartley | December 5, 2025, Form 8-K, Exhibit 10.2 |
| *†10.59 | Form of 2025 Performance Stock Unit Award Agreement pursuant to the Axogen, Inc. 2019 Stock Incentive Plan, as amended and restated as of March 27, 2024 | May 8, 2025, Form 10-Q, Exhibit 10.1 |
| *10.60 | Form of 2025 Restricted Stock Unit Award Agreement pursuant to the Axogen, Inc. 2019 Stock Incentive Plan, as amended and restated as of March 27, 2024 | May 8, 2025, Form 10-Q, Exhibit 10.2 |
| 21.1 | Subsidiaries of the Registrant. | Filed herewith |
| 23.1 | Consent of Deloitte & Touche, LLP | Filed herewith |
| 24.1 | Power of Attorney | Included on signature page |
| 31.1 | Certification of Principal Executive Officer | Filed herewith |
| 31.2 | Certification of Principal Financial Officer | Filed herewith |
| 32.1 | Chief Executive Officer and Chief Financial Officer Certifications pursuant to 18 U.S.C. 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002 | Furnished herewith |
| 101 | Inline XBRL Document Set for the consolidated financial statements and accompanying notes in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K | Filed herewith |
| 101.INS | XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | Filed herewith |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | Filed herewith |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | Filed herewith |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | Filed herewith |
| 101.LAB | Inline XBRL Extension Labels Linkbase | Filed herewith |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | Filed herewith |
| Exhibit Number | Description | Filings Referenced for Incorporation by Reference |
| 104 | Inline XBRL for the cover page of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set | Filed herewith |
| * | Management contract or compensatory plan or arrangement. |
|---|---|
| † | Confidential treatment has been granted for portions of this Exhibit pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The confidential portions have been deleted and filed separately with the U.S. Securities and Exchange Commission. |
| †† | Confidential treatment has been requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission. |
| ††† | Portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K because the information is not material and is the type of information that the Company treats as private or confidential. The Company agrees to furnish an unredacted copy of this exhibit on a supplemental basis to the SEC or its staff upon request. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.